The estimated Net Worth of Michael Halpin is at least $2.31 Milion dollars as of 17 May 2024. Mr. Halpin owns over 5,195 units of Vericel Corp stock worth over $274,611 and over the last 5 years he sold VCEL stock worth over $412,077. In addition, he makes $1,619,450 as Chief Operating Officer at Vericel Corp.
Sign up
Mr. Halpin VCEL stock SEC Form 4 insiders trading
Michael has made over 21 trades of the Vericel Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,195 units of VCEL stock worth $28,001 on 17 May 2024.
The largest trade he's ever made was exercising 30,000 units of Vericel Corp stock on 21 December 2020 worth over $79,500. On average, Michael trades about 7,286 units every 66 days since 2019. As of 17 May 2024 he still owns at least 6,284 units of Vericel Corp stock.
You can see the complete history of Mr. Halpin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Halpin biography
Michael Halpin serves as Chief Operating Officer of the Company. Mr. Halpin joined Vericel in April of 2017 with over 28 years of regulatory, quality assurance, and clinical research experience with a variety of medical device, combination product, small molecule, biologic, and advanced therapy technologies. Prior to joining Vericel, Mr. Halpin was with Sanofi and Genzyme Corporation; most recently as vice president, North American region regulatory head with responsibility for Sanofi Genzyme’s rare disease, immuno-inflammatory, multiple sclerosis and other business unit products. Mr. Halpin has also served as vice president, regulatory affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Carticel®, Epicel®, and MACI®. Prior to Genzyme, Mr. Halpin held a number of regulatory, quality, and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard, and Abiomed. Mr. Halpin received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.
What is the salary of Michael Halpin?
As the Chief Operating Officer of Vericel Corp, the total compensation of Michael Halpin at Vericel Corp is $1,619,450. There are 1 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
How old is Michael Halpin?
Michael Halpin is 58, he's been the Chief Operating Officer of Vericel Corp since 2019. There are 8 older and 6 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
What's Michael Halpin's mailing address?
Michael's mailing address filed with the SEC is 64 SIDNEY STREET, , CAMBRIDGE, MA, 02139.
Insiders trading at Vericel Corp
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel oraz Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
What does Vericel Corp do?
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
What does Vericel Corp's logo look like?
Complete history of Mr. Halpin stock trades at Vericel Corp
Vericel Corp executives and stock owners
Vericel Corp executives and other stock owners filed with the SEC include:
-
Dominick Colangelo,
President, Chief Executive Officer, Director -
Michael Halpin,
Chief Operating Officer -
Dominick C. Colangelo Esq.,
CEO, Pres & Director -
Michael Halpin,
Chief Operating Officer -
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.,
Chief Medical Officer -
Dr. Jonathan M. Hopper,
Chief Medical Officer -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Robert Zerbe,
Independent Chairman of the Board -
Alan Rubino,
Independent Director -
Kevin McLaughlin,
Independent Director -
Heidi Hagen,
Independent Director -
Steven Gilman,
Independent Director -
Paul Wotton,
Independent Director -
Sandra Pennell,
Principal Financial Officer and Principal Accounting Officer -
Jonathan Siegal,
Principal Accounting Officer, VP & Corp. Controller -
Roland DeAngelis,
Sr. VP of Commercial Operations -
Heidi Hassen,
VP of HR -
Patrick J. Fowler,
Sr. VP of Corp. Devel. & Strategy -
Eric Burns,
Exec. Director of Financial Planning and Analysis & Investor Relations -
Joseph Anthony Mara Jr.,
CFO, Principal Accounting Officer & Treasurer -
Capital Management Lp Conso...,
-
Daniel Orlando,
Chief Operating Officer -
Gerard J Michel,
CFO and VP, Corp. Development -
Nelson M Sims,
Director -
Lisa Wright,
-
Joseph Anthony Jr Mara,
Chief Financial Officer -
Jonathan Siegal,
Principal Accounting Officer -
Jonathan Mark Hopper,
Chief Medical Officer -
Sean C. Flynn,
Chief Legal Officer